Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.

In the third ΔTG tertile, fenofibrate treatment showed a favorable trend toward lower all-cause mortality among early-diagnosed patients, with a significant age-by-treatment interaction (P interaction = 0.012), whereas no benefit was observed among late-diagnosed patients.

also in 993 other papers

A borderline significant interaction was found between the age at hyperlipidemia diagnosis and lipid-lowering treatment for CVD death ( P interaction = 0.07) (Supplementary Table 3), that the beneficial effect of fenofibrate in reducing CVD death was observed only in the early-diagnosed (HR 0.47; 95% CI 0.30–0.74; P = 0.001), but not in the late-diagnosed (HR 0.87; 95% CI 0.55–1.40; P = 0.573) hyperlipidemia group.

also in 6,883 other papers

Fenofibrate treatment was also associated with a lower incidence of MACEs in patients with an earlier diagnosis, although the interaction did not reach statistical significance for this endpoint.

also in 75,281 other papers